Sensorium Therapeutics

A CNS Portfolio With Blockbuster Potential

About this Event

Sensorium Therapeutics is dedicated to solving some of the most devastating challenges in brain health. The company was founded by a world-class team of trailblazers in chemistry, neuroscience, and psychiatry from Harvard Medical School and Massachusetts General Hospital.

Sensorium currently has four key assets:
  • A rapid acting drug for anxiety that is entering clinical trials in June 2025. This drug, if successful, has been estimated by a third party market research firm to reach blockbuster status selling $3-5B per year. It will be an attractive program for large pharma partnership and acquisition.
  • A lead compound for treatment-resistant epilepsy, demonstrating remarkable efficacy in multiple preclinical seizure models.
  • Cognition-enhancing lead molecules, discovered through and currently fully funded by an NIH Small Business Innovation Research (SBIR) grant.
  • A discovery platform that that accelerates and de-risks drug discovery for CNS diseases.

CNS disorders, such as anxiety, epilepsy, depression and Alzheimer’s disease, have significant patient populations with limited effective treatments, presenting substantial market opportunities for successful therapies.

Because of this, Big Pharma is showing renewed interest in the CNS arena as evidenced by Johnson & Johnson’s recent $15 billion acquisition of Intra-Cellular Therapies, BMS acquisition of Karuna for $14B, and AbbVie acquisition of Cerevel for $9B, aiming to bolster their neuroscience portfolios.

Register today to watch our webinar with Sensorium CEO, Dr. Jacob Hooker, to hear about Sensorium’s pipeline and fundraising goals. 

Video On Demand

– Recorded

April 8

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.